Search Close Search
Page Menu

Cancer Nexus Blog

UMass Chan is attending major cancer conference to share advances in cancer research

Friday, April 08, 2022
|

This year, the Cancer Center has six members with findings being presented at the American Association for Cancer Research (AACR) Annual Meeting. These presentations highlight our collaborations with other academic institutions and our relationships with industry partners, including aTyr Pharma, Verseau Therapeutics and The Jackson Laboratory.

Delighted for Marcus Ruscetti, PhD, who was selected as an AACR2022 NextGen Star, affording him the opportunity to have his work highlighted as a rising star in cancer research.

Don't miss out!

If you’re registered, check out their presentations, below:

 

 

Sunday, April 10 | 3:50 pm - 4:05 pm (CDT) | Mara Epstein, ScD

Minisymposium: Molecular Genomics of Cancer Risk and Prognosis

Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis

 

Monday, April 11 | 1:30 pm - 5:00 pm (CDT) | Michael Brehm, PhD and Dale Greiner, PhD

Poster Session: Humanized Mouse Models, Imaging, and Immuno-Oncology

Enhanced development of functional human innate immune cells in a novel FLT3null NSG mouse strain expressing human FLT3L

 

Monday, April 11 | 1:30 pm - 5:00 pm (CDT) | Michael Brehm, PhD and Dale Greiner, PhD

Poster Session: Immune Response to Therapies 1

A novel, rapid, sensitive, and reproducible in vivo platform to assess efficacy and toxicity of bispecific antibodies

 

Monday, April 11 | 1:30 pm - 5:00 pm (CDT) | Hira Goel, PhD, and Arthur Mercurio, PhD

Poster Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1 / Chemistry

ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway sensitizes highly aggressive and chemoresistant TNBC subtypes to chemotherapy

 

 

Wednesday, April 13 | 11:04 am - 11:19 am (CDT) | Marcus Ruscetti, PhD

Major Symposium: Aging and the Tumor Microenvironment's Impact on Minimal Residual Disease and Cancer Recurrence

Modulating cellular senescence to reinstate natural killer cell immunity for pancreatic cancer immunotherapy